CD4+ T cells are not required for suppression of hepatitis b virus replication in the liver of vaccinated chimpanzees

Journal of Infectious Diseases

Volumn 213, Issue 1, 2016, Pages 49-56

  Rybczynska, Jolanta ^a,b   Campbell, Katherine ^c   Kamili, Saleem ^b   Locarnini, Stephen ^e   Krawczynski, Krzysztof ^b   Walker, Christopher M ^c,d  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e Victorian Infectious Disease Reference Laboratory   (Australia)

Author keywords

hepatitis B virus; persistence; vaccine; sterilizing immunity; CD4+ T cell; class II epitope.

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA; EPITOPE; HEPATITIS B VACCINE; P PROTEIN, HEPATITIS B VIRUS; POL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CHIMPANZEE; CONTROLLED STUDY; DNA DETERMINATION; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; LIVER PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; GENETICS; IMMUNOLOGY; LIVER; PAN TROGLODYTES; VIROLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; LIVER; PAN TROGLODYTES; VIRUS REPLICATION;

EID: 84962031607     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv348     Document Type: Article

References (31)

1. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-73
2. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142: 333-41
3. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-84
4. Lu CY, Chiang BL, Chi WK, et al.Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40: 1415-20
5. Jilg W, Schmidt M, Deinhardt F. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet 1990; 335: 173-4
6. Shouval D, Locarnini S. Increased prevalence of HBV envelope mutants in Taiwan: an emerging public health risk or a false alarm? Gastroenterology 2012; 143: 290-3
7. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23: 39-46
8. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63: 1021-51
9. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364: 236-47
10. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993; 17: 475-9
11. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995; 126: 716-21
12. Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013; 145: 1026-34
13. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49: 1483-91
14. Bocher WO, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld KH, Lohr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999; 29: 238-44
15. De Rosa SC, Lu FX, Yu J, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173: 5372-80
16. Stubbe M, Vanderheyde N, Pircher H, Goldman M, Marchant A. Characterization of a subset of antigen-specific human central memory CD4+ T lymphocytes producing effector cytokines. Eur J Immunol 2008; 38: 273-82
17. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-7
18. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-9
19. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76
20. Franco A, Guidotti LG, Hobbs MV, Pasquetto V, Chisari FV. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol 1997; 159: 2001-8
21. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-62
22. Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol 2004; 172: 483-92
23. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883-95
24. Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 2008; 13: 161-75
25. Bauer T, Weinberger K, Jilg W. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology 2002; 35: 455-65
26. Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652-62
27. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013; 33: 167-77
28. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-27
29. Banatvala JE, Van Damme P. Hepatitis B vaccine -do we need boosters? J Viral Hepat 2003; 10: 1-6
30. Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992; 11: 3413-20
31. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol 2010; 58: 258-66